SOX11 and neoplasm: Similarly, in a group of 127 patients at late tumor invasion stage (T3+T4), 63 cases (49.6%) of the SOX11-positive group showed longer medium survival (43.0 months) than the other 64 cases (50.4%) of the SOX11-negative group (23.0 months) patients (P=0.004, Fig. 6C, right).